We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

195 hedge funds and large institutions have $2.15B invested in Kite Pharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 82 increasing their positions, 42 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 19

95% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 42

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

14% more capital invested

Capital invested by funds: $1.88B → $2.15B (+$267M)

13% more funds holding

Funds holding: 173195 (+22)

23% less call options, than puts

Call options by funds: $68.3M | Put options by funds: $88.7M

Holders
195
Holders Change
+22
Holders Change %
+12.72%
% of All Funds
5.2%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
43
Increased
82
Reduced
42
Closed
19
Calls
$68.3M
Puts
$88.7M
Net Calls
-$20.4M
Net Calls Change
-$39.9M
Name Holding Trade Value Shares
Change
Change in
Stake
DILH
101
Dai-ichi Life Holdings
Japan
$1.17M -$58.1K -1,042 -5%
N
102
Nuveen
North Carolina
$1.13M -$15.5K -279 -1%
Kayne Anderson Rudnick Investment Management
103
Kayne Anderson Rudnick Investment Management
California
$1.1M +$1.1M +19,655 New
CIS
104
Capital International Sarl
California
$1.07M +$1.06M +19,100 New
Stifel Financial
105
Stifel Financial
Missouri
$1.06M +$757K +13,586 +253%
Citigroup
106
Citigroup
New York
$1.01M +$438K +7,865 +76%
Creative Planning
107
Creative Planning
Kansas
$994K -$135K -2,422 -12%
EA
108
Emerald Acquisition
Washington
$955K +$494K +8,872 +108%
MAP
109
Moody Aldrich Partners
Massachusetts
$862K +$86.4K +1,550 +11%
CAM
110
CG Asset Management
New York
$843K +$457K +8,200 +119%
SGH
111
Sivik Global Healthcare
Connecticut
$838K -$279K -5,000 -25%
AWCI
112
Alpine Woods Capital Investors
New York
$838K
TI
113
Turner Investments
Pennsylvania
$795K +$793K +14,230 New
BG
114
Bellevue Group
Switzerland
$782K
TD Asset Management
115
TD Asset Management
Ontario, Canada
$762K +$421K +7,550 +124%
Jane Street
116
Jane Street
New York
$752K +$750K +13,465 New
AIM
117
Assured Investment Management
New York
$746K +$744K +13,352 New
CG
118
Cutler Group
California
$736K +$240K +4,300 +48%
EIM
119
Essex Investment Management
Massachusetts
$728K +$726K +13,035 New
JC
120
Jetstream Capital
Tennessee
$726K +$724K +13,000 New
VIA
121
Vident Investment Advisory
Georgia
$721K -$13.5K -243 -2%
First Trust Advisors
122
First Trust Advisors
Illinois
$701K +$700K +12,557 New
Marshall Wace
123
Marshall Wace
United Kingdom
$578K -$4.61M -82,701 -89%
LPL Financial
124
LPL Financial
California
$576K -$44.6K -801 -7%
BL
125
BCWM LLC
Kansas
$570K +$9.92K +178 +2%

KITE Hedge Fund Activity: Q3 2016 in Review

195 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q3 2016, worth a combined $2.15B — up 14% from $1.88B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new KITE positions and 19 closed out — a net gain of 24 holders — while 82 added to existing stakes and 42 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $39.9M. The largest seller was Viking Global Investors, cutting an estimated $112M.

  • 195 institutional investors held Kite Pharma, Inc. (KITE) as of Q3 2016, up from 173 in Q2 2016.
  • Funds reported $2.15B of Kite Pharma, Inc. stock for Q3 2016, up 14% quarter-over-quarter.
  • 43 funds opened new Kite Pharma, Inc. positions in Q3 2016 and 19 closed out, a net change of +24 holders.
  • The largest Kite Pharma, Inc. buyer in Q3 2016 was Waddell & Reed Financial, an estimated $39.9M added.
  • The largest Kite Pharma, Inc. seller in Q3 2016 was Viking Global Investors, an estimated $112M sold.

Based on aggregated 13F filings for Q3 2016.